Different tumor models in vivo demonstrated that DTX2 inhibitor treatment inhibited tumor growth and sensitized HCC cells to the therapeutic effects of programmed cell death protein 1 (PD‐1) antibody. Here, DTX2 is linked to hepatocellular carcinoma.